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1CHAPTER 1. INTRODUCTION
Streptococcus pneumoniae is the primary cause of bacterial pneumonia and
contributes to millions of deaths worldwide annually.  The current capsule polysaccharide
based vaccines do provide some protection, but the 7 to 23 valent formulations cannot protect
against the over 90 serotypes currently known. Pneumococcal surface protein A (PspA) is a
promising candidate for a protein-based vaccine against S. pneumoniae, showing protection
in immunized mice and providing the advantage of universal protection from all serotypes of
the bacterium.  This project shows the results of immunizing CBA/N mice intranasally and
subcutaneously with PspA encapsulated into a novel polyanhydride nanoparticle delivery
platform in attempt to create a protective protein-based pneumococcal vaccine against
bacterial challenge.
Literature Review
Vaccination History
Immunization, the practice of developing immunity to a pathogen by a controlled
exposure to the specified microbe or a component it produces, has been one of the great
success stories of science and medicine.  This claim is best exemplified by the story of
controlling the dreaded disease of smallpox.  Attempts to induce resistance to the smallpox
virus Variola major have been documented in 16th century China, 18th century Europe, and
colonial America (46, 82).  These early attempts would use pathogen-containing pus from
infected individuals to inoculate healthy people, an approach that possessed a risk of
developing severe side-effects or the actual disease from the virulent virus.  Incidences of
death from this process of ‘variolation’ claimed to be 1 % or less, which was a stark
2improvement from the up to 30 % death rate of those who contracted smallpox naturally (8).
In the 1790’s, Edward Jenner of England conducted the same procedure with the milder
cowpox virus Vaccinia, another member of the orthopox virus family, with much reduced
side-effects and was still able to confer immunity to the more deadly smallpox virus (18).
Smallpox ‘vaccination’ based on this live Vaccinia virus method by Jenner continued
through the 20th century, eventually leading to the declaration by the World Health
Organization (WHO) in 1980 that naturally contracted smallpox had been eradicated
worldwide (9).
In the late 1800’s, the field of microbiology had taken root and techniques to reduce
pathogen virulence were being developed by multiple scientists such as Pasteur, Toussaint,
Salmon, and Smith (19) to name a few.  With the knowledge gained by studying the
cultivation of disease causing microbes, whole cell vaccines were generated by utilizing in
vitro tissue growth or non-host animal passages of the microbes to attenuate them, meaning
that their virulence was reduced (50).  This allowed people to be exposed to a weakened form
of the actual causative agent for a disease and to develop specific immunity to the pathogen,
rather than relying on cross reactivity as seen with the Variola and Vaccinia viruses.
Vaccines for yellow fever (12), measles, mumps, rubella, varicella, tuberculosis, and polio
were created from attenuated infectious agents (86).
At the turn of the 20th century, scientists utilized similar bench top processes to tackle
the issue of creating vaccines against toxin-producing microbes.  Substances such as formalin
and aluminum salt precipitations in combination with prolonged heating created the first
toxoid (inactivated microbial toxin) vaccines to diphtheria and tetanus in the 1920’s.  These
inactivated toxins combined with mammalian antiserum, usually from horses or sheep,
3created the first toxoid vaccines (15, 69).  Such diseases as typhoid, cholera, pertussis, and
typhus began to be countered by comparable bench top techniques, which would create killed
whole cell vaccines to protect against these disease-causing pathogens (86).
With utilizing attenuated live microbes in vaccine formulations, there runs a risk of
reversion to the fully virulent pathogen, and killed, whole cell vaccines can produce highly
noticeable and undesirable side-effects after administration.  In attempt to counter these
circumstances, molecular techniques were employed to identify and produce immunogenic
components of pathogens to make minimal antigen (i.e., subunit) vaccines.  In more recent
decades, technology has advanced to allow for better recombinant antigen production and
purification from microbial pathogens.  Since the days of purification from whole cell or
virus cultures, recombinant DNA technology has become a common tool in the laboratory for
producing and isolating whole or subunit proteins (45).  The inherent nature of such
procedures also contributes to a better knowledge and characterization of the pathogenic
mechanisms of the infectious agent and the necessary components needed for a protective
vaccine formulation.
Adjuvants
While producing and utilizing non-viable vaccines (such as toxoids) against microbial
pathogens, it was observed that these formulations, while producing fewer side-effects, also
created less protective immunity in people (69).  Fortunately, some of compounds used as co-
precipitates to prepare the early diphtheria and tetanus toxoids proved to enhance the
immunogenicity of these microbial components.  The use of alums (aluminum salts) became
common and were the first adjuvant (an immune enhancing vaccine additive) approved for
4human use in the United States (63).  In the first half of the 20th century, oil-in-water
adjuvants also became popular.  These formulations, similar to alums, help to create a depot
effect and the gradual exposure of an antigen to the host, which lengthens the time of an
antigen’s presence to the immune system, resembling a replicating microbe.  But with the
improved immune responses induced by the oil-in-water adjuvants, there arose some
troublesome side-effects.  The popular oil-in-water Freund’s adjuvants were extremely
effective, but could induce a degree of autoimmunity in some individuals after vaccination
(45, 63).  There were also concerns that some of the slow degrading oils or surfactants used
could become carcinogenic.  The alum salts, while milder in their inflammatory effects, can
produce granulomas at injection sites and their adjuvanticity was not reproducible from batch
to batch of vaccine (63).  Increasing safety concerns like these helped to promote the
expansion of adjuvant research; however, it is also becoming more difficult for new
adjuvants/immune stimulators to get approved.
Similar to vaccines, the development of new adjuvants started to focus on microbial
components, chemical molecules, or microbial subunits in order to enhance vaccine
immunogenicity.  Bacterial cell wall components such as waxes from mycobacteria, or lipids
from Salmonella were isolated and tested.  Some of these compounds would have greater
specificity for stimualting specific components of the immune system allowing for immune
response targeting.  These targeting systems frequently fall into one of two categories,
delivery systems or immune stimulators (45).
Immune stimulating components that are being studied are frequently molecules that
are recognized by immune cells. Constituents such as monophosphoryl lipid A (MPLA), a
modified component from surface membranes of the Gram negative bacterium Salmonella
5minnesota, the protein flagellin from bacterial locomotive appendages, and unmethylated
bacterial CpG-rich DNA all have specific receptors on most immune cells (45, 74). Each
receptor to these immune stimulators induces activation of the immune cells often with
characteristic outcomes, allowing for immune reactions against intracellular or extracellular
pathogens to be initiated (54).
Adjuvants that enhance the delivery of vaccine antigens tend to be in the micrometer
to nanometer scale, mimicking the size of bacterial and viral pathogens and allowing them to
disseminate within body tissues and lymphatics (14, 74).  Liposomes and virosomes are
simple spheres of a lipid composition and thus are able to hold membrane bound surface
antigens.  The immune stimulating complexes (ISCOMS) are a more complex mixture of
lipids, cholesterol, saponins, and antigens which can provide a more robust immune
stimulation because of their heterogeneity (45).
Recently, MPLA was approved for use as an adjuvant in the new human papilloma
virus vaccine, and, thus, became the second approved vaccine adjuvant for use in the United
States (2). In 2009, the vaccine Cervarix, which is composed of virosomes loaded with L1
antigen from two human papilloma virus strains and adjuvanted with a combination of
aluminum hydroxide and MPLA, was approved for use in teenagers in a three dose regimen
(27).  The combined use of delivery (alum) and immunostimulating (MPLA) adjuvants
together in a vaccine such as Cervarix can enhance the effectiveness of a subunit vaccine
resulting in protective immunity (26).
6Variation in Vaccine Effectiveness: Stimulation of the Immune Response
Why are these vaccines successful at producing protection against pathogens?  Within
the body is a system of various molecules, hematopoetic (i.e., blood derived) cells, and
tissues that react to infectious agents in order to eliminate them, and these innate and
adaptive components together create the immune system (52).
When a pathogen first crosses the primary physical and chemical barriers of the body,
such as mucosal epithelia, skin, and secreted antimicrobial molecules and enzymes, they are
encountered in the bodily tissues by phagocytic cells.  Typically macrophages and dendritic
cells (DCs) move through tissues sampling for foreign matter, which they recognize by
pattern recognition receptors (PRRs). Many microbes have repeating patterns of protein, lipid,
and/or carbohydrates on their surfaces which are well conserved and thus good targets for
recognition and are referred to as pathogen-associated molecular patterns (PAMPs) (54).
Intracellular pathogens can also be recognized by some internal classes of PRRs that reside in
the cytoplasm and intracellular membrane compartments, thus allowing the phagocytic cells
to alert other immune components of the invading microbe.  PRRs can initiate the
internalization of the invading microbes by phagocytosis and their subsequent destruction in
the lysosome.  These processes also induce the production of cytokines that are released from
activated phagocytes to initiate local inflammation and alert other immune cells to the region
of infection (52).
The four hallmarks of inflammation are 1) swelling from vasodilatation and edema,
2) heat, 3) redness from the influx of blood, and 4) slight pain from the pressure of the extra
fluid. It is this rush of blood that brings additional lymphocytes and neutrophils to assist in
the continued clearance of foreign microbes (35). If any microbial cells escape into the blood
7stream, a cascade system of serum proteins, called the complement system, is also
bacteriocidal.  There are three variations of the complement cascade which are triggered by
different starting components.  These triggers are antibody-bound to pathogens, mannose-
binding lectin which binds bacterial surface carbohydrates, or activation of the C3
complement protein by alternative means resulting in the binding to exposed hydroxyl
residues on the bacterial surface (56).  When the complement cascade is completed, no
matter the initiation pathway, an approximately 10 nanometer pore is formed in the cell
membrane by the membrane attack complex that results in the disruption of the delicate ion
and solute balance within the bacterial cell (35).
Dendritic cells, after ingesting a microbe at the site of infection, mature and migrate
to regional lymph nodes via the lymphatic vessels.  The ingestion and breakdown of the
invading pathogen generates many small peptide fragments within the phagolysosome which
the cell then displays on surface proteins called major histocompatability complexes (MHC)
(54).  In the lymph node follicles, DCs interact with local naïve B and T lymphocytes,
searching for the T cell that will recognize the antigenic peptide-loaded into the MHC
molecule on the surface of the DC.  When a lymphocyte’s (T cell receptor, TCR) and DC’s
(MHC I or II) surface receptors bind, a secondary surface receptor binding event occurs to
stablized the interaction so lymphocyte activation can begin (52). A release of cytokines from
the DC triggers the lymphocyte to differentiate into a specific effector cell.  The lymphocyte
then actively proliferates, differentiating into short-lived effector cells, and long-lived
memory cells.  Once a primary infection is cleared, it is the memory lymphocytes which will
be able to respond quickly to any subsequent infections by the same pathogen (55).
8The B cell is the lymphocyte that differentiate into plasma cells that then secrete
antibodies, which are critical for the defense against extracellular bacteria, viruses, and toxins.
There are two types of binding site on the Y-shaped antibodies, the two arms (i.e., Fab) are
for binding the antigenic epitopes (molecular conformations along the antigen) and the
carboxy terminal end (i.e., Fc) for binding with the Fc receptors on phagocytic cells or to
complement protein (Figure 1) (52).  The interaction of the antigen binding site (the Fab) to
the foreign cell or toxin marks it for destruction and prevents it from interacting with and
possibly destroying host cells, processes called opsonization and neutralization, respectively.
It is this component of the antibody that vaccines try to specify for their antigen, so that upon
re-infection with the same microbe the antibody will immediately recognize the critical
virulence components of the invader and help eliminate it before the infection becomes
established and leads to host tissue damage (54).
Antigen specific plasma cells were once thought to possess short life spans to only
produce antibody in times of need (e.g., during an infection).  When there is no antigen to
stimulate antibody production in the body, the cells would die and memory B cells would
remain as sentinals until the next infection prompts them to proliferate.  More recently, it has
been discovered that plasma cells can become long-lived and quietly produce transient
amounts of antibody from their niches in the bone marrow or spleen for years or even
decades (13, 75).  Experiments designed to track the persistence of plasma cells in mice
depleted of memory B cells (13), showed that plasma cells can be long-lived and continue to
produce antigen-specific antibody (33).
B cell activation to create antibodies can happen independently of interaction with T
effector cells.  If molecular structures on a microbe’s surface are highly repetitive and
9promote good binding and cross-linking of the B cell receptor (membrane bound antibodies),
then B cell activation can occur independent of T cell help (75).  The antibodies produced
following T cell-independent stimulation of B cells tend to be less diverse and less avid than
those that were produced following a T cell-dependent interaction.  Antibodies produced
\ Fc /
Figure 1.  Basic antibody structure. Antibodies are composed of two identical heavy chains (in blue) and two
identical light chains (in red), and are held together by covalent disulfide bonds (denoted SS).  The variable
region of one heavy and one light chain together create an antibody antigen binding fragment (Fab), or antigen
binding site.  The ends of the heavy chains constant regions (CH3) together create the antibody receptor binding
site. Figure from Moser and Leo, 2010.
in this manner also tend to be short-lived, which can become troublesome with frequent re-
infections that can cause disease.  The target for creating the most avid (more strongly
binding) antibody memory to antigens therefore requires T cell interactions (37, 86).
Pneumonia
Pneumonia is a respiratory disease caused by many different microbes, including
bacteria, viruses, and fungi.  Such pathogens are transmitted via respiratory droplets and
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cause inflammation in deep lung tissues when they bypass the innate defenses of the
nasopharyngeal region (4).  All ages of humans worldwide are susceptible, especially
children under 5 years of age, the elderly, and any who have chronic conditions that may
impair the immune system.  Every year, hundreds of thousands of children die from
pneumonia and it remains one of the leading causes of childhood death around the globe (1,
58), prompting the development of the Global Coalition Against Child Pneumonia in 2009
(10). Pneumonia can occur as a secondary infection when the immune system has been taxed
by another illness such as influenza (32, 48, 58).  Community environments contribute to
disease development as well through crowded quarters, increasing person to person
transmission, and air pollution from smoke and chemicals which depress ciliary action in the
trachea (5, 48).
Streptococcus pneumoniae
The bacterium Streptococcus pneumoniae is the primary cause of bacterial
pneumonia.  It is a Gram positive, polysaccharide capsule-producing extracellular microbe
which naturally inhabits the human nasopharynx and can asymptomatically colonize a vast
majority of a population (1).  There are over 90 serotypes, or capsule polysaccharide variants,
that have been identified and all capsular types contribute in varying degrees to immune
avoidance by the pathogen. This polysaccharide coat prevents the phagocytosis of S.
pneumoniae via direct recognition by innate phagocytic cells, such as macrophages, that
normally rely on the use of PRRs or bacteria-bound C3b complement protein (11).  Only
when the bacterium is opsonized by IgG antibodies can it be readily phagocytosed and
cleared from the site of infection (54).  Yu et al. (85) have found that as little as 1.0 g/mL of
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secreted polysaccharide is enough to thwart antibody-mediated opsonization of S.
pneumoniae, thus, reducing the clearance of S. pneumoniae by phagocytic cells.
In this regard, a capsule-based pneumococcal vaccine has been available for many
decades to curtail the incidence of pneumonia caused by S. pneumoniae.  At the turn of the
21st century, a newer version of this vaccine was released, and has helped to boost immunity
to some of the most at risk groups for contracting S. pneumoniae-mediated respiratory
disease.

Current Pneumococcal Vaccines
PPSV23, PCV7, and PCV13
The 23-valent pneumococcal polysaccharide vaccine (PPSV23) was the first multi-
serotype vaccine developed against S. pneumoniae.  The PPSV23 was approved for use in the
United States in 1983 and contains 23 pneumococcal polysaccharide antigens in isotonic
saline solution, with a 0.25 % phenolic preservative.  Currently, this vaccine is recommended
for children over two years of age or those who have medical conditions that may pre-
dispose them to pneumococcal infection (59).
The pneumococcal conjugate vaccines (PCV) have capsular polysaccharide
covalently linked to nontoxic, cross-reactive material (CRM) carrier protein from C.
diphtheriae.  These are suspended in succinate buffer with aluminum phosphate adjuvant.
The PVC7 vaccine contains polysaccharides from seven S. pneumoniae serotypes that cause
the vast majority of reported pneumonia cases in the United States.  In 2000, the FDA
approved use of this vaccine for children under two years of age employing a multiple-dose
schedule.  In 2010, the PVC13 pneumococcal vaccine was approved for use in the United
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States.  The main difference between the PCV7 and PCV13 is the inclusion of six additional
serotype polysaccharides in the 13-valent conjugated vaccine (59).
Outcomes of Vaccine Use
Over the past decade, worldwide use of the PCV7 vaccine as part of routine
vaccination schedules has produced commendable results in reducing the incidence of early
childhood pneumonia.  While bacterial carriage is not eliminated, vaccination has decreased
the incidence of serious invasive pneumococcal diseases (IPD) (59).  IPD can cause such
complications as otitis media, meningitis, and bacteremia; a condition that can be especially
serious for children younger than five years (59).  A noticeable drop in prevalence of
vaccine-included serotypes has been seen in bacterial isolates grown from pneumonia cases
as well (70, 85).
Part of this success is due to the composition of the PCV vaccines in comparison to
the PPSV23.  The inclusion of a protein carrier attached to the capsule polysaccharide (a T
cell-independent antigen, which is also a weak immunogen) enhances the immune system’s
response to the polysaccharide by promoting T cell help, as evidenced by promoting an
adaptive response.   The aluminum phosphate adjuvant in the PCV formulation also provides
an immediate innate immunity stimulator for recruiting leukocytes (54).  In addition, the
wide-spread use of PPSV23 as a general booster after 18 to 23 months of age has shown
signs of protection in PCV vaccinated children (70).
Obstacles
The capsule-polysaccharide based vaccines, while effective, still require multiple
doses for the best results.  When the recommended vaccination schedule is followed a child
can receive three to four immunizations in the first 18 months of life for pneumococcus alone.
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Russell et al. (70) found that a minimum of two vaccinations before the age of 12 months,
plus a PPSV23 booster at 18 months, was required for noticeable protection from S.
pneumoniae to occur.  While the PCV vaccines can be given at the same time as other infant
immunizations, patient compliance in maintaining clinic visits can become difficult, even
more so in developing countries (64).  This multiple immunization schedule also requires a
lot of vaccine product to be purchased, and this can quickly become expensive.
The other limitations associated with the use of the polysaccharide vaccines are that
they only protect against the specific bacterial serotypes to which the included capsule types
match. All three of the discussed vaccine formulations contain capsule polysaccharides from
the S. pneumoniae strains that have been epidemiologically identified as the most prevalent
in causing disease.  But, as these strains are reduced or eliminated from the nasopharyngeal
region, other serotypes not included in the vaccine formulations become established (70, 85).
Unless these emerging capsule types are included in the current polysaccharide vaccines, no
serotype-specific immune memory can be developed.  Countries and regions of the world
also vary in which S. pneumoniae serotypes are most prevalent in their reported cases of
pneumonia and IPD (48, 64).  In these areas of the world, even if a full 3 dose PCV
vaccination schedule is administered, the reduction in disease-causing strains may be 30-
40 % less than in American clinical use (42).
To address some of these obstacles, many researchers are now looking at the
possibility of using protein antigens expressed on the S. pneumoniae cell wall as potential
vaccine candidates.  With recombinant protein technology far more advanced than
polysaccharide production and synthesis, there is the potential for greatly reducing the cost of
production for a new pneumococcal vaccine.  The use of a recombinant protein antigen also
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raises hopes of being able to induce protective immunological memory in all age groups
including children.
Pneumococcal Surface Protein A
In order for an antibody-mediated immune response to prevent infection, it must
recognize antigens that are secreted or expressed on the extracellular surface of a microbe.
Thus, proteins presented on the S. pneumoniae cell wall have been the primary target of new
vaccine antigen searches.  Despite the presence of a polysaccharide capsule, some virulence-
associated proteins are sufficiently exposed on the surface of S. pneumoniae such that
antibodies can bind and effect opsonization or complement fixation (29).  With the advent of
modern molecular biology techniques, these proteins can be readily cloned and the resultant
recombinant proteins used for research purposes including vaccine development.
One extensively studied protein is pneumococcal surface protein A (PspA), which has
many variants.  Despite there being three family types of this protein expressed in S.
pneumoniae covering 6 different clades, immunization of mice with recombinant PspA leads
to demonstrable antibody-mediated protection across multiple capsular serotypes (38), and
sometimes can be cross-reactive between protein clades (30, 51).  All PspA proteins share a
similar structure (as shown in Figure 2) which consists of a N-terminal alpha-helical coiled
region, a proline rich intermediate region, and a C-terminal choline binding domain which
attaches to liptotechoic acids within the bacterial cell wall (29).  Recent research has
uncovered that certain portions of this protein are accessible to antibody above the secreted
capsule (30).  The function of PspA is to bind apolactoferrin, an iron binding and
bacteriocidal serum protein and prevent it from reaching the bacterial cell surface (72); and to
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bind immune-activating complement protein to prevent deposition and opsonization on the
cell surface (60).
In order for a protein such as PspA to be part of an effective subunit vaccine the
delivery of stable, structurally in tact protein antigen within the body is essential in the
vaccine design.  Current work with polyanhydride nanoparticles for antigen delivery is
showing great promise for recombinant protein vaccine application, and demonstrating
protection in initial in vivo experimentation.
Figure 2.  Representation of pneumococcal surface protein A (PspA) secondary structure. This cartoon
represents the overall structure of PspA and its attachment to the Streptococcus pneumoniae cellular surface.
The protein is bound to lipotechoic acids protruding from the cell wall by non-covalently binding to choline
moieties with its C-terminal end.  The coiled N-terminal portion protrudes out from the capsule polysaccharides
where it is available for binding to apolactoferrin or antibodies. Figure originally from Daniels, et al., 2006.
Polyanhydrides
For over a decade, biodegradable polyanhydride polymers have been approved for
human use with the drug-releasing product Gliadel, an implantable wafer loaded with an anti-
cancer therapeutic drug (3).  These polymers offer the great advantages of controlled release
of their load due to surface erosion degradation, and the resultant carboxylic acid by-products
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are biocompatible and induce no adverse side-effects in vivo (76).  These load-releasing
properties can be fine tuned further by the creation of copolymers with varying erosion
kinetics by adjusting the molar ratio of the two polyanhydride monomers used to formulate
the polymers.
The commonly used sebacic acid (SA) erodes quickly and the homopolymer can
deliver the entirety of the encapsulated product in little more than a week within the body.
An aromatic polyanhydride called 1,6-bis(p-carboxyphenoxy)hexane (CPH) is more
hydrophobic than SA, and the resulting homopolymer has a slower degradation rate (months
to years) which would facilitate the persistence of the encapsualted payload after being
implanted or injected (76).  Previous studies have demonstrated that copolymer formulations
of these two compounds encapsulating an immunogenic protein can induce robust antibody
responses in mice against known immune-stimulating antigens, such as tetanus toxoid,
administered in a single vaccination dose (44).  These results were similar to more traditional
multiple dose vaccination regimen employing soluble antigen, and promoted a memory cell
response upon in vitro stimulation of isolated T cells from vaccinated mice as well (79).  A
third, more amphiphilic polyanhydride chemistry called 1,8-bis(p-carboxyphenoxy)-3,6-
dioxaoctane (CPTEG), which is based on CPH with triethylene glycol moieties added into
the monomer backbone (78), can also be utilized to tailor the erosion characteristics of a
copolymer as well as facilitate the stability of the encapsulated protein.
The incorporation of CPTEG into a copolymer results in a polymer particle with the
erosion characteristics between bulk and surface erosion, which can allow for a better “burst”
of antigen release when administered.  This initial burst that releases some of the
encapsulated immunogen enhances the initiation of the immune response against the
17
delivered antigen. The remaining protein payload within the polyanhydride particles is
released gradually, prolonging antigen persistence and is believed to facilitate the affinity
maturation of antibody and inducte long-lived memory lymphocytes for the specific antigen
(44).  Affinity maturation is a key component for the development of an efficacious
antibody-based protective immune response.
A B
C
Figure 3. Molecular structure of polyanhydride polymers.  Molecular stuctures of A) sebacic acid, B) 1,6-
bis(p-carboxyphenoxy)hexane, and C) 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane.
Polyanhydride copolymer formulations can also enhance interactions with some
phagocytic cell PRRs due to their hydrophobicity, thus, enhancing the uptake of the nano-to-
micro scale particles and subsequent presentation of processed immunogens to the adaptive
immune system (68, 81).  The adjustment of the monomer ratios in the polymer formations
as well as particle size can be used to tailor the kinetics of the resultant immune response
induced against a particular encapsulated antigen.  Repeating patterns on the surface of the
polyanhydride particles, such as oxygen containing repeats, can also encourage phagocytic
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update by mimicking PAMP-like patterns and activating antigen presenting cells (79).  Work
experimenting with surface modification of the polyanhydride particles with
monosaccharides or disaccharides common to bacterial surfaces has shown that these
modified particles are more readily internalized by DCs cells, encouraging antigen
presentation and subsequent activation of T lymphocytes (22, 24).
The process by which polyanhydride nanoparticles are produced, which includes a
cold anti-solvent method, provides a production process that is less degradative for protein
antigens, better preserving their secondary structure and immunological epitopes (23, 66).
With near 100 % encapsulation efficiency, this method of polymer fabrication also greatly
reduces the amount of protein needed to produce or formulate a vaccine preparation (77).
The nanoscale size of the produced particles facilitates the dispersion of the antigenic load
through the lymphatic vasculature to draining lymph nodes from the site of injection,
reducing the dependence for DC uptake and migration to secondary lymphoid tissue in the
regional lymph nodes (14).
Recently a 50:50 CPTEG:CPH polyanhydride nanoparticle formulation administered
in a single intranasal vaccination showed protection against the bacteria Yersinia pestis, the
cause of pneumonic plague (80).  The combination of soluble antigen in buffer, to prompt a
primary immune response, combined with nanoparticle-encapsulated protein, for prolonged
release and exposure, was 100 % protective in laboratory mice against a bacterial challenge
up to 23 weeks after a single immunization.  The persistent antibody observed in the mouse
serum, as well as its high avidity (compared to the MPLA adjuvanted control) demonstrates
the potential of the polyanhydride nanoparticle platform to create viable single dose
19
vaccinations (80).  With this published procedure as a guide, our attempt to create a single
dose protein-based pneumococcal vaccine was tested.
Experimental Purpose
The purpose of the experiments described in the following sections was to determine
if recombinant PspA encapsulated into polyanhydride nanoparticles would induce protective
immunity against a lethal S. pneumoniae challenge in mice.  The regularly utilized
recombinant protein PspA/Rx1 (AA1…302) (7), consists of the N-terminal alpha-helical
region and a portion of the proline rich mid-section of the native bacterial protein, was the
antigen used.  Because a previous single dose protein-loaded nanoparticle regimen had been
used to successfully protect C57BL/6 mice against a lethal challenge with Yersinia pestis
(80), we hypothesize that a single immunization with PspA encapsulated into this vaccine
delivery platform will induce protective immunity against a lethal challenge of S.
pneumoniae.
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CHAPTER 2. MATERIALS AND METHODS
Materials
Monomer Synthesis
The materials used for monomer synthesis include sodium hydroxide, hydrobenzoic
acid, dibromohexane, 1-methyl-2-pyrrolidinone, and triethylene glycol, which were
purchased from Sigma Aldrich (St. Louis, MO).  Acetone, sulfuric acid, potassium carbonate,
dimethyl formamide, toluene, acetonitrile, N,N-dimethylacetamide, and acetic acid were
purchased from Fisher Scientific (Fairlawn, NJ). 4-p-fluorobenzonitrile used in the synthesis
of CPTEG monomer was purchased from Apollo Scientific (Chesire, UK).  Sebacic acid
monomer was purchased from Sigma Aldrich (St. Louis, MO).
Acetylation, Polymerization, and Nanoparticle Fabrication
The following chemicals were used for acetylation and polymerization.  Acetic
anhydride, ethyl ether, petroleum ether, chloroform, methylene chloride, and hexane were
purchased from Fisher Scientific (Fairlawn, NJ). Deuterated chloroform and dimethyl
sulfoxide were used in 1H NMR analysis of the polymers and monomers, respectively, and
were purchased from Cambridge Isotope Laboratories (Andover, MA). Pentane and
methylene chloride used in nanoparticle fabrication were purchased from Fisher Scientific
(Fairlawn, NJ).
Recombinant protein and Bacterial Stocks
All Streptococcus pneumoniae strains used in these studies as well as recombinant
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pneumococcal surface protein A (PspA) (UAB055, PspA/Rx1 AA1…303) were generously
provided by Dr. David Briles of the University of Alabama in Birmingham. Streptococcus
pneumoniae was cultured on trypticase soy agar petri plates supplemented with 0.5 % yeast
extract and 5 % sheep blood (blood agar) or in brain heart infusion (BHI) broth medium
supplemented with 0.5% yeast extract at 37 °C overnight.
Bacteriological medium and Taxo P-discs containing optochin, for S. pneumoniae
verification, were purchased from BD Biosciences (Franklin Lake, NJ) and fresh whole
sheep blood (with acid citrate dextrose to prevent clotting) was obtained from the USDA
National Animal Disease Center facility (Ames, IA). Gentamicin sulfate salt used in blood
agar plates, to select for Gram + bacteria like S. pneumoniae, for colony forming unit (CFU)
determination was purchased from Sigma-Aldrich (St. Louis, MO).
Endotoxin Removal and Lyophilization of Antigen
Endotoxin removal was performed with Miltenyi endotoxin removing magnetic beads
(Auburn, CA). The Limulus amoebocyte lysate assay from Lonza (Switzerland) was used to
evaluate the endotoxin levels in protein stocks.  Dialysis cassettes of 10 kDa cutoff were
purchased from Thermo Scientific (Rockford, IL), and the lyophilizer used was from VirTis
(Gardiner, NY).
Immunizations
The components used to create vaccines were phosphate buffered saline (PBS, 0.05
M and pH 7.4) from Mediatech, Inc. (Manassas, VA) and monophosphoryl lipid A (MPLA)
was purchased from Sigma-Aldrich (St. Louis, MO).
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Antibody Evaluations
Enzyme Linked Immunosorbent Assay
Assay components include microtiter 96 well high-binding plates were from Corning
Costar (Tewksbury, MA), granulated gelatin from BD Biosciences (Franklin Lake, NJ),
Tween 20 from Fisher Scientific (Fairlawn, NJ), and goat serum from Sigma-Aldrich (St.
Louis, MO). Alkaline phosphatase-conjugated goat anti-mouse detection antibodies for IgG
(H+L), IgG1, and IgG2a were purchased from Jackson ImmunoResearch (West Grove, PA).
The phosphatase substrate was obtained from Fisher Scientific (Pittsburgh, PA) and was
solublized in sodium carbonate (50 mM) magnesium chloride (2 mM) buffer (pH 9.3).
Avidity Assay
MagPlex-C microspheres of xMap technology reagents were purchased from
Luminex (Austen, TX).  The flat bottom 96 well plates, BioPlex 200 machine, BioPlex Pro II
plate washer, and BioPlex Manager 6.0 software were purchased from BioRad Laboratories
(Hercules, CA).  Detection reagents, anti-mouse polyclonal IgG biotin-conjugated antibody
and streptavidin-phycoerythrin (PE) (0.2 mg/mL), were purchased from eBioscience (San
Diego, CA).
Animals
Five to eight week old female CBA/CaHN-Btkxid/J mice were purchased from Jackson
Laboratory (Bar Harbor, ME) and were housed in specific pathogen-free conditions where
bedding, cages, and feed were sterilized before use.  All procedures performed were
approved by the Iowa State University Institutional Animal Care and Use Committee.
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Methods
Monomer Synthesis
The CPH and CPTEG monomers were fabricated as previously described (28, 78).
The synthesis of 1,3-bis(p-carboxyphenoxy)propane from 4-hydrobenzoinc acid was adapted
using 1,6 dibromohexane. First, sodium hydroxide and hydrobenzoic acid were dissolved in
water and heated to 100 °C under refluxing conditions.  Dibromohexane was then added
dropwise and the solution was allowed to react for at least 5 hours, or until all of the solution
had formed a white precipitate. The product was then dissolved in water, and concentrated
sulfuric acid added until a pH of 2 was reached. The precipitate was filtered and redissolved
in acetone to remove impurities. The recrystallization step was repeated until all impurities
were removed from the product, as determined by 1H NMR (Varian VXR300).
The CPTEG monomer was synthesized from triethylene glycol, dimethyl formamide,
and potassium carbonate. First, a dinitrile was formed by reacting triethylene glycol and
potassium carbonate in dimethyl formamide and toluene.  This solution was reacted at 170 ˚C
under refluxing conditions until all of the toluene was distilled.  This was followed by the
addition of 4-p-fluorobenzonitrile and the resultant solution was heated at 160 °C for 12
hours. Next a diacid was formed. Most of the solvent was removed using a rotary evaporator
followed by the addition of water, acetic acid and sulfuric acid. The solution was refluxed
under nitrogen at 170 °C for 6 hours. The resultant solution was precipitated in deionized
water and the product collected. The product was redissolved in acetonitrile and filtered.
Recrystallization was performed until purity was confirmed by 1H NMR.
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Prepolymer Synthesis (Acetylation)
Pre-polymers of CPH and SA were synthesized from monomers as previously
described (73).  In order to perform the acetylation, the SA and CPH monomers were heated
to 100 °C under reflux conditions and nitrogen purge.  The solution was allowed to reflux for
30 minutes before the solvent was completely removed through rotary evaporation. The
resultant mixture was then dissolved in chloroform and precipitated with equal parts
petroleum and ethyl ether.
Polymer Synthesis
Polymers and co-polymers of CPH, CPTEG, and SA were synthesized through melt
condensation as previously described (43, 78).  Polymer purity and molecular weight was
determined using 1H NMR and gel permeation chromatography (Waters GPC, Milford, MA)
was used to confirm molecular weight.
Endotoxin Removal and Lyophilization of Antigen
Endotoxin was removed from the PspA protein stocks using endotoxin removal
magnetic beads per the manufacturer’s instructions with 82-85 % protein recovery, and
endotoxin levels were assessed using a chromogenic Limulus amoebocyte lysate assay
according to the manufacturer’s instructions.  By using this procedure, the endotoxin content
was reduced from 80 EU/mg protein to 1.9 EU/mg protein. A portion of this PspA
preparation was dialyzed against sterile deionized water using a dialysis cassette in sterile
equipment at 4 oC for 18-20 hours.  This protein was then frozen at -80 oC in a sterile vial for
25
1 hour, and lyophilized at -50 oC overnight. The lyophilized PspA was stored frozen on
dessicant until used in protein-loaded nanoparticle fabrication.
Nanoparticle Fabrication
The PspA-loaded polyanhydride nanoparticles were formulated using a solvent-anti
solvent precipitation method as previously described (49, 67, 81).  PspA (sufficient for 1 %
loading) and polyanhydride polymer were dissolved in methylene chloride at a concentration
of 20 mg/mL. The solution was then sonicated at an output of 40 Hz (VibraCell) to ensure a
homogenized mixture.  The resulting solution was then rapidly added to pentane at a ratio of
1:250 at room temperature for the CPH:SA formulation or at -40 °C for the CPTEG:CPH
polymers due to the lower glass transition temperature for these polymer formulations.
Nanoparticles were then collected from the solution using vacuum filtration.  Nanoparticles
were characterized using scanning electron microscopy (FEI Quanta SEM, Hillsboro,
Oregon) and size distribution was determined from resultant images using ImageJ software.
Prior to use, the nanoparticles were stored in a dessicator at -80 oC.
Immunizations
Subcutaneous
Eleven to 14-week-old CBA/N mice were immunized subcutaneously at the nape of
the neck on experimental day zero with the treatments described in Table 1; there were six
mice per group. Protein suspended in PBS with or without MPLA was administered first,
followed by the 1 % PspA loaded nanoparticle formulations. Prior to administration, the
nanoparticles were suspended in PBS and sonicated at 40 Hz for 10-15 seconds.  The MPLA
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x 3 treatment group received three immunizations in total, administered on days 0, 21, and 42.
Blood samples for antibody analyses were collected via the saphenous vein at -2, 14, 28, 49,
and 59 days post-immunization.
Table 1.  Immunization dose compositions. The majority of the CBA/N mice were immunized once on day
zero. *MPLA 3X dose group received immunizations at day 0, 21, and 42. In the IN immunization experiment
n = 8, and for the SC immunization experiment n = 6. IN = intranasal administration, SC = subcutaneous
administration at the nape of the neck, NP = not performed, PBS = phosphate buffered saline pH 7.4, PspA =
pneumococcal surface protein A, MPLA = monophosphoryl lipid A, CPTEG:CPH = 50:50 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane : 1,6-bis(p-carboxyphenoxy)hexane, CPH:SA = 20:80 1,6-bis(p-
carboxyphenoxy)hexane : sebacic acid.
Component
Treatment Group PBS (L)IN / SC
PspA
(g/dose)
MPLA
(g/dose)
CPTEG:CPH
(g/dose)
CPH:SA
(g/dose)
Control 50 / 100 --- --- --- ---
PspA Only 50 / NP 25
MPLA X 3* 50 / 100 8.33 10 --- ---
MPLA X 1 50 / 100 25 10 --- ---
CPTEG:CPH 50 / 200 25 --- 500 ---
CPTEG:CPH + MPLA NP / 200 25 10 500 ---
CPH:SA NP / 200 25 --- --- 500
CPH:SA + MPLA NP / 200 25 10 --- 500
Intransal
Eight-week-old CBA/N mice were immunized intranasally (IN) on experimental day
zero with either the saline, MPLA x 1, MPLA x 3, 25 µg PspA in PBS, or CPTEG:CPH
treatments described in Table 1, with 8 mice per group. Prior to IN immunization, mice were
anesthetized by administering an intraperitoneal injection (80 L) of a 20 mg/ml ketamine / 1
mg/ml xylazine cocktail; once immobilized, the mice were held vertically and a 25 L
volume of the designated vaccine formulation was administered to each nare, resulting in a
50 L total vaccination volume. Immediately prior to administration, the nanoparticles were
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added to the soluble protein solution and sonicated at 40 Hz for 10-15 seconds to assure
suspension. The MPLA x 3 treatment group received three immunizations administered on
days 0, 21, and 42. Blood samples for antibody analyses were collected via the saphenous
vein at -4, 14, 28, and 49 days post-immunization. Because of the magnitude of the antibody
responses measured in the serum samples collected at day 49, a subcutaneous booster
immunization of 5 µg PspA (100 µL PBS total volume) was administered (day 56) to mice in
the protein only treatment group and the CPTEG:CPH nanoparticle treatment group.
Bacterial Challenge
Streptococcus pneumoniae serotype A66.1 was grown overnight, and about 15-25
colonies were taken from the blood agar plate to inoculate 10 mL of BHI broth medium as
described above. The cultures were incubated until an optical density of 0.45-0.50 at 600 nm
was reached. A fraction of bacterial culture was diluted in PBS to create the inoculum. One
hundred microliters of the prepared inoculum was taken and serially diluted and plated for
actual CFU counts (full method description in Appendix). CBA/N mice were intravenously
challenged at 8-9 weeks post-immunization with 1.01 x 107 (subcutaneously immunized, OD
= 0.533) or 3.75 x 105 (intranasally immunized, OD = 0.493) CFU via the tail vein in a 200
L volume. Prior to the intravenous injection, the mice were placed under a heat lamp for 3-5
minutes to dilate the tail veins.  The mice were observed three times per day for clinical signs
of infection including ruffled fur, hunched backs, lethergy, and ability to respond to stimuli
(full description in the Appendix, Table 2). Body temperature was monitored once daily with
a Fluke-566 infrared thermometer (Fluke Corporation, Everett, WA).  Mice found moribund
were euthanized by CO2 asphyxiation and necropsied. After euthanasia, blood was collected
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via cardiac puncture, and the right lung and spleen were collected to measure bacterial
burden (data not shown).
Antibody Evaluations
Enzyme Linked Immunosorbent Assay
Microtiter 96 well plates were coated with PspA (0.5 g/mL in 100 µL PBS per well)
and allowed to bind overnight at 4 oC.  Plates were washed three times with PBS and then
blocked with 2 % granulated gelatin prepared in PBS supplemented with 0.05 % Tween 20
(PBS-T) for 2 hours at room temperature.  Plates were placed at 37 oC for 10 minutes to
liquefy the gelatin, then washed three times with PBS-T.  Individual mouse serum samples
were diluted 1:100 or 1:200 in the first well of a 96 well microtiter plate in duplicate, and
then serially diluted two- or three-fold in PBS-T supplemented with 1 % goat serum for titer
assessment.  For the assessment of IgG isotypes, serum samples were diluted 1:500 and
tested in duplicate wells. Serum antibodies were allowed to bind overnight to the microtiter
plates coated with PspA at 4 oC.  Plates were washed three times with PBS-T and 100 L of
alkaline phosphatase-conjugated goat anti-mouse IgG (H+L), IgG1, or IgG2a antibody (1
g/mL in PBS-T supplemented with 1% goat serum) was added to the wells and incubated
for 2 hours at room temperature.  Plates were washed four times with PBS-T and 100 L of
phosphatase substrate (1 mg/mL) in 50 mM sodium carbonate and 2 mM magnesium
chloride buffer (pH 9.3) was added and the colorimetric changes were measured at 405 nm
after 15 minutes (for isotypes) or 30 minutes (for titer) of incubation.
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Avidity Assay
MagPlex-C microspheres (magbeads) were activated and coupled to PspA (20 µg/mL
in PBS) as described by the manufacturer.  Following the conjugation step, the PspA-
magbeads were washed with PBS-T and stored in PBS with 1 % bovine serum albumin and
0.05 % sodium azide and covered to block overnight at 4 oC.  Serum samples were diluted in
PBS-T and 50 L was added to each well of a 96 well flat bottom microtiter plate along with
50 L of vigorously vortexed magbeads (120,000/mL) conjugated with PspA suspended in
blocking buffer.  Plates were immediately covered and placed on a plate shaker for 1 hour at
room temperature.  Plates were washed three times using a BioPlex Pro II plate washer with
the blocking buffer, and 100 L of either PBS-T or with 6 M urea in PBS were added to the
appropriate wells.  Plates were covered and put on a shaker for 15 minutes, and then washed
three more times.  Biotin-conjugated goat anti-mouse IgG was diluted 1:200 and 50 L was
added to each well, and plates were covered and shaken at room temperature for 1 hour.  The
plates were washed three times, and 50 µL of streptavidin (PE) diluted 1:20 was added to
each well and the plates were incubated for 30 minutes.  Plates were washed three times, 125
L of blocking buffer added to the wells, and the mean fluorescent intensity was measured
using a BioPlex 200.  To calcualte the relative avidity of a serum sample having a
demonstrable antibody response to the target antigen, the mean fluorescent intensity (MFI)
obtained for the sample well treated with urea was divided by the MFI measured for the
corresponding serum sample wells incubated only with PBS-T.  This value was multiplied by
100 to obtain a relative percent binding for each serum sample.
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Statistics
Statistics were run with SAS JMP program using the Student’s t-test, p < 0.05.
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CHAPTER 3. RESULTS
Intranasal Immunization Antibody Response
Having shown previous success with a single dose intranasal nanoparticle
immunization inducing protective immunity against Yersinia pestis (80), the present studies
outline experiments that were performed to evaluate the intranasal immunization of mice
with recombinant PspA loaded into 50:50 CPTEG:CPH nanoparticles in order to effect
protective immunity against Streptococcus pneumoniae.  Seven weeks after intranasal
vaccination (see Table 1), mice that were immunized three times with the PspA plus MPLA
formulation developed anti-PspA antibody titers that were approximately 100,000 to 200,000.
In contrast, the anti-PspA antibody response measured at seven weeks in the mice receiving
the single dose nanoparticle formulation only reached a maximal titer of 1,000 to 2,000 that
was significantly less (p ≤ 0.05) than that induced by the triple dose MPLA regimen (Figure
4, part A).  To assess whether the mice receiving the nanoparticle formulation had been
primed to respond with an anamnestic response, the nanoparticle treated mice, as well as the
PspA only mice, received a subcutaneous booster immunization (5 g PspA).  After the
booster dose, the resultant IgG1 produced by the two previously mentioned treatment groups
showed a marginal increase at day 66 compared to the response at day 49 (Figure 4, part C).
While the titer in the PspA only group increased by more than 10-fold, the total IgG (H+L)
titer in the mice immunized with the 50:50 CPTEG:CPH formulation increase only 2- to 3-
fold.  With respect to the quality of the antibody response (i.e., avidity), the anti-PspA
antibody induced following immunization with the nanoparticle regimen showed higher
avidity at all time points measured while it took longer for the avidity to reach a similar value
in the treatment groups immunized with PspA plus MPLA (Figure 4, part B).
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Figure 4. Assessment of the serum IgG responses following intranasal immunization of CBA/N mice with
PspA. A) Using serial two-fold dilutions, serum antibody titers were measured by ELISA. B) Post-
immunization anti-PspA antibody avidity was measured at days 28 and 66. C) Isotype switching was assessed
by measuring the IgG1 and IgG2a PspA-specific antibody in serum samples collected at days 49 and 66.  All
serum samples were collected prior to Streptococcus pneumoniae A66.1 challenge. Full procedures are detailed
in the Materials and Methods section. n = 8, except for MPLA X 3 where n = 6. Statistics were calculated with
SAS JMP using Student’s t-test, p < 0.05. * = group boosted with 5 g PspA in phosphate buffered saline (pH
7.4) at 53 days post-immunization. IN = intranasal immunization, PspA = pneumococcal surface protein A,
MPLA = monophosphoryl lipid A, CPTEG:CPH = 50:50 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane: 1,6-
bis(p-carboxyphenoxy)hexane.
Bacterial Challenge of Intranasally Immunized CBA/N
To test the protection of the humoral immunity induced by the intranasal
immunizations, CBA/N mice were challenged with 3.75 x 105 CFU of S. pneumoniae strain
A66.1.  As can be seen in Figure 5, the triple dose MPLA treatment produced 83 % survival
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of the mice following intravenous challenge through the two week observation period. While
75 % of the mice that were immunized with PspA encapsulated into 50:50 CPTEG:CPH
nanoparticles survived through day five, less than 30 % of these mice survived beyond day 9
post-challenge . The mice that were immunized once with PspA adjuvanted with MPLA
succumbed to bacteremia faster than the naive control mice, with none of the mice in this
group surviving after 11 days.
Figure 5. Survival of intranasally immunized CBA/N mice following challenge with Streptococcus
pneumoniae A66.1. Mice were intravenously challenged with 3.75 x 105 CFU of strain A66.1 in a 200 L
volume 70 days after the initial immunization. The mice were monitored daily for clinical signs of infection as
described in the Materials and Methods of the Appendix.  n = 8, except for MPLA X 3 where n = 6.  PspA =
pneumococcal surface protein A, MPLA = monophosphoryl lipid A, CPTEG:CPH = 50:50 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane: 1,6-bis(p-carboxyphenoxy)hexane.
Subcutaneous Immunization Antibody Response
Based on the poor protective response induced following intranasal immunization,
CBA/N mice were subcutaneously immunized with the same vaccine regimen as above with
the addition of the 20:80 CPH:SA PspA loaded nanoparticles.  Because of the benefits
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detected with the inclusion of MPLA in the IN vaccine regimen, the effect of MPLA added
along with the nanoparticle treatments was also examined for subcutaneously vaccinated
mice (e.g., CPTEG:CPH + MPLA and CPH:SA + MPLA).  Following subcutaneous
immunization, the 50:50 CPTEG:CPH nanoparticle vaccination groups produced anti-PspA
IgG titers 10 times higher than those induced by intranasal administration (Figure 6, part A).
Of note, the mice immunized once with the MPLA plus PspA regimen developed a titer of
10,000, which was similar in magnitude to that induced by the same immunization given
intranasally.  The inclusion of MPLA in the soluble portion of the vaccine regimen did
double the overall anti-PspA titer induced by the mice immunized with the nanoparticle
treatments (e.g., 50:50 CPTEG:CPH + MPLA and 20:80 CPH:SA + MPLA), but did not
contribute to higher IgG2a:IgG1 isotype ratios (Figure 7).  The mice immunized
subcutaneously with the triple dose of PspA plus MPLA produced antibody titers that were
about 2- to 3-fold greater than that induced by intransal immunization with the same
treatment.  At 8.5 weeks post-immunization, there was no statistical difference in avidity
between any of the nanoparticle immunized mice regardless of the addition of MPLA (Figure
6, part B).
Bacterial Challenge of Subcutaneously Immunized Mice
Eight and a half weeks after the initial subcutaneous immunization, CBA/N mice
were challenged intravenously with 1.01 x 107 CFU of S. pneumoniae strain A66.1.
Stunningly, all of the treatment groups, regardless of their immune status, began to succumb
on day two post-challenge.  By 4 days post-infection, mouse survival had dropped to about
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Figure 6. Assessment of serum IgG responses following subcutaneous immunization of CBA/N mice with
PspA. A) Collected serum was serially diluted two-fold and assessed by ELISA.  B) Anti-PspA antibody
avidity measured post-immunization.  The treatment identification is the same as in part A.  C) Anti-PspA
antibody isotype switching assessed by IgG1 and IgG2a amount in serum 59 days post-immunization.  Full
procedures are detailed in the Materials and Methods section. Statistics were calculated with SAS JMP using
Student’s t-test, p < 0.05.  SC = subcutaneous immunization, PspA = pneumococcal surface protein A, MPLA =
monophosphoryl lipid A, CPTEG:CPH = 50:50 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane: 1,6-bis(p-
carboxyphenoxy)hexane, CPH:SA = 20:80 1,6-bis(p-carboxyphenoxy)hexane: sebacic acid.
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25-33 % across all vaccinated groups while 50 % of the non-immunized mice survived
(Figure 8).
Immunization Route Comparison
From the previously described bacterial challenges administer to PspA-immunized
mice, protein delivered with MPLA in a three dose regimen showed better protection (e.g.
survival) when administered intranasally compared to subcutaneous vaccination.  The
treatment produced similar isotype ratios in both routes though, with just a 2- to 3-fold
difference in pre-challenge titer (Figure 7).
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Figure 7. Comparison of the IgG2a:IgG1 ratios induced following intranasal or subcutaneous
immunization with PspA.  Pre-bacterial challenge serum samples from 66 days post-immunization
(intranasally immunized) and 59 days post-immunization (subcutaneously immunized) were analyzed and
IgG2a:IgG1 ratios compared. n = 8, except for MPLA X 3 where n = 6 (intranasally immunized), or n = 6
(subcutaneously immunized). Statistics were calculated with SAS JMP using Student’s t-test, p < 0.05.  IN =
intranasal immunization, SC = subcutaneous immunization, PspA = pneumococcal surface protein A, MPLA =
monophosphoryl lipid A, CPTEG:CPH = 50:50 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane: 1,6-bis(p-
carboxyphenoxy)hexane, CPH:SA = 20:80 1,6-bis(p-carboxyphenoxy)hexane: sebacic acid.
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Figure 8.  Survival of subcutaneously immunized CBA/N mice following challenge with Streptococcus
pneumoniae A66.1. Intravenous challenge with 1.01 x 107 CFU of strain A66.1 in a 200 L volume was
administered 63 days post-initial immunization.  The mice were monitored daily for clinical signs of infections
as described in the Materials and Methods of the Appendix.  n = 6.  PspA = pneumococcal surface protein A,
MPLA = monophosphoryl lipid A, CPTEG:CPH = 50:50 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane: 1,6-
bis(p-carboxyphenoxy)hexane, CPH:SA = 20:80 1,6-bis(p-carboxyphenoxy)hexane: sebacic acid.
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CHAPTER 4. DISCUSSION
Streptococcus pneumoniae is the primary cause of bacterial pneumonia worldwide
with over 90 serotypes that have been identified (1, 11, 64). The capsule polysaccharide
based 23-valent PPSV23 and 7-valent PCV vaccines have shown beneficial results due to
worldwide use (59) but obstacles remain, especially in the limited number of serotypes
targeted within the vaccines and the use of poorly immunogenic polysaccharide antigen to
which the most at risk populations cannot mount good immune responses against without a
multiple dose vaccine regimen (55, 70, 75). With the help of recombinant protein technology
pneumococcal surface protein A has become a well-studied surface protein of S. pneumoniae
and has shown protective immunity in adjuvanted multi-dose regimens in many mouse
strains, inducing demonstrable antibody-mediated protection across multiple capsule
serotypes characterized by IgG isotype switching (30, 34, 51, 53, 62).  However, multiple-
dose immunization schedules in humans pose the risk that doses will be missed due to poor
patient compliance.  To overcome this, nanotechnology offers the possibility to design
efficacious, single dose vaccines against a variety of pathogens including S. pneumoniae by
using polyanhydride nanoparticles, which can gradually release intact protein antigen over a
period of weeks in mice (44, 66). Previous work from this laboratory has demonstrated that a
50:50 CPTEG:CPH vaccine with encapsulated F1-V antigen from Yersinia pestis was able to
provide 100 % protection in mice 23 weeks after a single immunization (80); the protective
immune response was characterized by a high titer and high avidity serum antibody that
persisted for the length of the study.  These findings provided the basis for the PspA-loaded
polyanhydride nanoparticle vaccine formulation used in these studies.
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Survival of Intranasally Immunized Mice to Lethal Bacterial Challenge
Based on the previous results obtained with F1-V antigen encapsulated into
nanoparticles (80), CBA/N mice were intranasally immunized with PspA-loaded 50:50
CPTEG:CPH nanoparticles or PspA adjuvanted with MPLA to test for the production of a
protective immune response. As shown in Figure 5, the mice immunized with three doses of
PspA adjuvanted with MPLA showed 83 % survival following an intravenous challenge with
S. pneumoniae A66.1.  However, the percentage of mice surviving the challenge in all
remaining immunization groups was 12-25 % by day 14 post-infection.  The protection
induced by the three doses of PspA adjuvanted with MPLA appeared to be mediated by a
combination of a high titer, ≥ 100,000 IgG (H+L), anti-PspA response (Figure 4) along with
a more balanced IgG2a:IgG1 antibody response (Figure 7) which has been demonstrated
previously (62).  It is reasonable to hypothesize that the higher circulating antibody titer
present in the mice immunized three times would have opsonized more of the bacterial cells
injected into the bloodstream, thus, clearing a majority of the S. pneumoniae early in the
infection.  The mice immunized with the nanoparticles, on the other hand, had 100 times
lower anti-PspA antibody titer and would not have been able to effectively opsonize as many
bacterial cells for clearance by phagocytes, thus, allowing S. pneumoniae to avoid
elimination resulting in tissue damage (based on gross anatomy observation at necropsy) and
death of the mice.
Based on the host responses in the mice immunized once with PspA adjuvanted with
MPLA, it is apparent that the MPLA + PspA vaccine administered once was not sufficient to
produce protective immunity against a S. pneumoniae challenge.  In fact, the weak immune
response induced by a single immunization with MPLA + PspA proved to be detrimental to
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survival, with all the mice succumbing to the bacterial infection by day 11 post-inoculation.
Even with a IgG antibody titer 10 times higher than that induced by the nanoparticle regimen
and the induction of both IgG1 and IgG2a anti-PspA responses, it proved not to be protective.
The mice immunized with the 50:50 CPTEG:CPH nanoparticle regimen did receive a
subcutaneous booster immunization two weeks prior to bacterial challenge, and, as seen in
Figure 4 part C, this did boost the serological anti-PspA IgG1 response, while the single dose
MPLA IgG1 levels were waning. This result may hint at the necessity of multiple
immunizations for the mucosal route of vaccination in order for the protective immunity to
be induced (20, 34, 53). Immunoglobulin G1 is a complement activating antibody, so higher
levels of this antibody in the blood should help to kill extracellular bacteria more efficiently,
but could also promote a more vigorous complement-induced inflammatory response.  For
high capsule producing serotypes of S. pneumoniae that can prevent efficient antibody
binding to their surface (85), it is reasonable to hypothesize that the bacteria would also be
able to protect their cell membrane from damage induced by the  complement’s membrane
attack complex.  If the levels of IgG2a, which binds to phagocytic cell Fc receptors to
promote bacterial uptake (55) are low or unable to bind due to the capsule, then the
complement activating IgG1 may promote more local tissue damage than protection.
While the single dose, encapsulated-protein nanoparticle vaccine did not induce
protection, the increase in the mean survival time suggests that an efficacious nanoparticle
vaccine could be developed. In comparison to the intranasal immunization, previous work by
this group utilizing several protein immunogens has demonstrated that more robust antibody
titers are induced following subcutaneous administration; therefore,  mice were immunized
by the subcutaneous route to assess the ability to induce protective immunity.
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Subcutaneously immunized CBA/N mice fail to produce a protective humoral immune
response
It was an unanticipated outcome of these studies that CBA/N mice receiving the
subcutaneous immunization failed to survive more than 4 days post-inoculation (Figure 8).
Of the subcutaneously immunized mice, 66 - 82 % of the mice succumbed to the infection
while 50 % of the non-vaccinated mice survived.  The addition of MPLA to the nanoparticle
regimen appeared to be advantageous with respect to the increase in total anti-PspA IgG titer,
but this improvement in the titer failed to contribute to protection.  The addition of MPLA
appears to have detrimental effects with respect to the maintenance of the long-lived
antibody response as evidenced by the more rapid decrease over time in the overall IgG titer
in these mice (Figure 6, part A). What is most striking was how rapidly the immunized mice
succumbed to the infection.  This precipitous onset of death within two days post-inoculation
suggests a possible immune-enhancement of pathogenicity of the bacteria, perhaps similar to
that previously seen with syncital respiratory virus vaccines (31, 41).  In the subcutaneoulsy
immunized mice, there were also observations of neurological side-effects (e.g., hind-limb
paralysis, inability to sit or stand upright, or maintain balance) in some of the mice, hinting at
an increased potential for the systemic infection to spread to the meninges. These side-
effects were most prominent in the mice receiving the single dose MPLA and 50:50 CPH:SA
treatment groups, with 33% of the mice from each group displaying a neurological disorder
within 2-3 days post-infection (bacterial challenge clinical signs of infection log
observations).
Despite the more robust IgG (H+L) titers produced by all the treatment groups
following the subcutaneous route of immunization, these titers proved more detrimental than
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protective upon bacterial challenge.  The IgG2a:IgG1 ratios of the single dose subcutaneous
vaccinations were equivalent to one another with a value of approximately 0.15 that signifies
a dominant IgG1 response.  Of interest, this low ratio is nearly half of that induced by the
intranasal immunizations suggesting that an IgG1 skewed isotype response is detrimental
(31).  Surprisingly, the IgG isotype values and overall ratio of IgG2a:IgG1 for the
subcutaneous, triple dose MPLA vaccination regimen were the same as those induced by the
protective intranasal immunization, yet, following subcutaneous administration, these
antibody characteristics were not associated with survival.
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CHAPTER 5. CONCLUSIONS
Based on the experiments described herein, it is clear that the single dose, PspA-
loaded polyanhydride nanoparticle vaccine used to immunize mice requires further
optimization in order to induce protective immuity.  While intranasal vaccination with the
nanoparticle regimen was moderately successful with respect to inducing anti-PspA serum
antibody, it was not capable of protecting mice from S. pneumoniae infection in comparison
to the mice multiply immunized with PspA plus MPLA.  Even with the great difference in
antibody production between these two vaccine formulations, the similarities in the anti-
PspA IgG responses between these two groups does show promise.  The PspA booster
immunizaton given to the nanoparticle treated mice may have serendipitously shown a need
for more than one immunization by the intranasal vaccination route in order to induce an
efficacious immune response.  Although a single nanoparticle immunization of 50:50
CPTEG:CPH has been successful in protecting mice against pathogens such as Y. pestis (80),
these recent results remind us of the need to tailor each vaccine for each different antigen
because the nature of the protective immune response may be as disparate as the pathogens
being studied.
The failure to induce protective immunity following subcutaneous immunization was
unexpected, especially considering the higher IgG (H+L) titers induced by the MPLA X 3
immunization regimen was protective when administered intranasally.  Because of the rapid
onset of death in the immunized mice, it appears that the subcutaneous immunizations
induced an immune-enhanced pathogenicity.  The best known case of a vaccine inducing
immune-enhanced pathogenicity was with a formalin-inactivated respiratory syncytial virus
(RSV) in the 1960’s, when immunized children showed greater disease development and
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hospitalization after vaccination. Investigations as to the cause of this outcome suggested
that immune complexes activating the complement cascade, in combination with a
predominantly TH2 T-cell response, promoted a high granulocytic cell infiltration and
inflammatory activation in the lungs (31).  A recent study using MPLA incorporated into
virosomal RSV vaccine showed promise in promoting a more balanced IgG2a:IgG1 ratio and
TH1 skewed adaptive response to a two-dose intramuscular immunization regimen (41).  The
mucosal route of vaccination appears to promote a better protective immune response against
S. pneumoniae infection compared to a parenteral route of immunization. This suggests that
further studies are warranted to develop an efficacious vaccine regimen using the
polyanhydride nanoparticle delivery platform.
The polyanhydride single dose pneumococcal vaccine formulation that was tested did
not induce comparable immune responses relative to those induced by a more conventional,
multiple dose vaccine regimen.  While less than optimal, these results have provided
invaluable insight as to how to tailor a vaccine to induce the desired immunity against an
important respiratory pathogen such as S. pneumoniae.  These results give hope for the
possibility of developing a minimal dose pneumococcal vaccine for the future.
Future Directions
The single intranasal nanoparticle vaccination, followed by one protein only booster
roughly 2 months post-immunization, provided valuable results suggesting that an antigen-
loaded polyanhydride nanoparticle induced protective immunity against bacterial challenge is
possible.  Further experimentation with this prime/boost regimen may give insight as to the
need for how many immunizations are required in order to produce effective mucosal
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immunity against S. pneumoniae.  Booster immunizations can be given at different time
points after the initial immunization (at 2 and 4 weeks, or 3 and 6 weeks), given by different
routes (intranasal or repeat the subcutaneous booster route), with or without additional
adjuvants, and with different polyanhydride chemistry ratios or combinations.  Additional
experiments can also be performed to investigate the protein dose needed to promote higher
anti-PspA antibody titers.  If the quality (i.e., avidity) of the humoral response can be
enhanced while maintaining a balanced IgG2a:IgG1 profile, there is a better likelihood of
creating a successful nanoparticle-based intranasal vaccine.
When a protective protein-based pneumococcal vaccination regimen has been
developed, experiments testing pneumococcal carriage in immunized and non-immunized
mice can be conducted.  With the potential risks of pneumonia and invasive pneumococcal
disease from bacterial colonization, there are many published reports evaluating the carriage
of S. pneumoniae in the respiratory tract and nasopharynx (16, 36, 40, 61, 83).  If it can be
confirmed that therapeutic vaccination can lower the carriage rate of the nasopharyngal-
localized S. pneumoniae, that may provide proof-of-principle that the concept of herd
immunity could be employed to reduce the public health threat associated with
pneumococcal colonization.
Investigation into the induction of  PspA-specific cell-mediated immunity is
warranted, especially in light of the results of the apparent immune-enhanced pathogenesis
observed following subcutaneous immunization.  Polyanhydride nanoparticles have been
shown to promote good cell-mediated immune responses (i.e., CD8+ T cells), and the
polyanhydride chemistries possess the potential to be modified to facilitate targeting of
specific immune cell populations. These functionalized nanoparticles may then promote
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better protective immunity against an extracellular, mucosally-associated pathogen like S.
pneumoniae (22, 24).
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APPENDIX: SYSTEMIC PNEUMOCOCCAL MOUSE INFECTION
MODEL
Introduction
Inbred laboratory mice have been a popular animal model for investigating
mammalian organ systems and human disease for decades.  With their small size and rapid
reproductive rate, mice can economically be housed and bred while allowing in vivo
experiments to be conducted in a matter of months rather than years.  With multiple mouse
varieties having fully sequenced genomes the creation of knockout strains further enhances
their usefulness in research by allowing investigations into how and why certain phenotypes
or genotypes influence a response to a procedure, environment, or diet.
The C57BL/6 mouse strain is a popular and affordable mammalian model in small
animal research.  Being well characterized many knockout strains of this mouse variety exist
including strains with immunological deficiencies, which creates the potential for in depth
elucidations of the mechanisms associated with the host response to a vaccine.  For these
reasons, we tested the potential of the C57BL/6 mouse strain for use in a mouse model of
pneumonia.
The CBA/N mouse strain contains a tyrosine kinase deficiency in B cells which
affects normal B cell development and prevents the mice from effectively mounting
antibody-mediated immune responses to T-cell independent antigens, in particular, to
polysaccharide antigens (55, 65).  This is important because the polysaccharide capsule
produced by Streptococcus pneumoniae, which helps the bacterium to evade opsonization
and killing by phagocytic cells within the mouse, cannot be effectively targeted in the
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CBA/N mice.  Without antibody to bind the polysaccharide capsule, it is difficult for immune
cells (e.g., macrophages, neutrophils) to effectively phagocytose S. pneumoniae; additionally,
deposition of proteins of the complement cascade on the bacterial surface, that would
otherwise be detrimental to the cell membrane, are also impeded (71).  The use of the CBA/N
mouse strain for modeling pneumonia can be considered as analogous to young children and
the elderly in humans, who are also poor responders to polysaccharide antigens produced by
a variety of mucosal pathogens. The increased susceptibility of these age groups to
encapsulated pathogens relates to either their underdeveloped or waning immune systems,
respectively (6, 55).
To establish a bacterial challenge model female C57BL/6 and CBA/N mice were
inoculated intravenously or intraperitoneally with infectious doses of S. pneumoniae strain
A66.1 ranging from 102 to 107 colony forming units (CFUs) in 100 L or 200 L volumes.
Previously published literature (16, 21, 25, 36, 39, 40, 61) varies widely on the number of
CFUs administered for a systemic infection model due to factors such as pneumococcal
strain, route of administration, and mouse strain; therefore, the experiments detailed below
utilized a broad range of CFU doses in order to establish the bacterial challenge model. Once
defined this systemic pneumococcal infection model can be used to evaluate the efficacy of
an anti-pneumococcal vaccine.
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Materials and Methods
Animals
Eight to nine week old female CBA/CaHN-Btkxid/J mice and C57BL/6 were obtained
from Jackson Laboratory (Bar Harbor, ME) or Harlan Laboratories (Haslett, MI),
respectively, and were housed in specific pathogen-free conditions where bedding, cages, and
feed were sterilized before use.  All procedures performed were approved by the Iowa State
University Institutional Animal Care and Use Committee.
Recombinant protein and Bacterial Stocks
All S. pneumoniae serotype strains used in these studies were generously provided by
Dr. David Briles of the University of Alabama in Birmingham. Streptococcus pneumoniae
was cultured on trypticase soy agar petri plates supplemented with 0.5 % yeast extract and
5 % sheep blood (blood agar) or in brain heart infusion (BHI) broth medium supplemented
with 0.5% yeast extract at 37 °C overnight.
Bacteriological medium and Taxo P-discs containing optochin, for S. pneumoniae
verification, were purchased from BD Biosciences (Franklin Lake, NJ) and fresh whole
sheep blood (with acid citrate dextrose to prevent clotting) was obtained from the USDA
National Animal Disease Center facility (Ames, IA). Gentamicin sulfate salt used in blood
agar plates, to select for Gram + bacteria like S. pneumoniae, for colony forming unit (CFU)
determination was purchased from Sigma-Aldrich (St. Louis, MO).
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Measurement of Bacterial Colony Forming Units (CFU)
Bacterial culture was grown overnight, and 1.0 mL of the overnight culture was used
to inoculate 10 mL of fresh broth; this was performed in duplicate. An aliquot of culture was
taken hourly, one aliquot was used to measure culture turbidity at OD600 and 100 L added to
a tube of 900 L phosphate buffer saline (PBS, 0.05 M, pH 7.4, Mediatech, Inc., Manassas,
VA) to create a 1:10 dilution.  After measuring the culture turbidity, 100 L of the primary
dilution was serially diluted into subsequent tubes containing 900 L PBS to a final dilution
of 1 x 10-6. For each dilution, 15 µL aliquots were spotted in triplicate onto separate section
of the same blood agar plate; and all six dilution aliquots were replicated on blood agar plates
with 4.0 g/mL gentamicin (Sigma-Aldrich, St. Louis, MO). When the liquid had absorbed
into the agar, the plates were incubated at 37 oC overnight.  The S. pneumoniae colonies on
both plates were counted, averaged, and CFU/mL calculated for samples collected at each
time point and were then equated back to the corresponding OD600. These results were
graphed (Figure 9) and used to estimate the CFU/mL for cultures of S. pneumoniae used to
challenge mice.
Bacterial Challenge
Streptococcus pneumoniae strain A66.1 was grown overnight on blood agar plates
and 15 to 25 colonies were used to inoculate 10 mL of BHI broth medium. The cultures were
incubated until an OD600 of 0.45-0.50 was reached. Using the graph in Figure 9, CFU/mL
was calculated for the culture and an aliquot of the bacterial culture was diluted in PBS to
create the inocula. One hundred microliters of each inoculum was serially diluted and plated
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Figure 9. Standard curve establishment based on optical density and colony forming units.  Seeded
bacterial cultures of Streptococcus pneumoniae strain A66.1 were sampled every hour to read an OD600 and
dilute a sample of culture 1:10, then serially dilute to 1.0 x 10-6.  These dilutions were plated on blood agar and
incubated at 37oC for 12 to 14 hours.  The CFUs grown were counted, and CFU/mL of culture was calculated
for each OD reading.
(described above) to get inoculum dose CFU counts.  To prepare mice for challenge, they
were placed under a heat lamp fitted with a 40 to 60 Watt bulb for three to five minutes to
dilate the tail veins for intravenous administration. Female C57BL/6 were challenged
intravenously with bacterial doses ranging from 244 to 3.5 x 106 CFU, and CBA/N mice
were challenged intravenously with 222 to 1.0 x 106 CFU.  All intravenous challenge inocula
were administered in a 200 L volume via the tail vein using a 26 gauge needle. The inocula
given intraperitoneally to C57BL/6 mice ranged from 222 to 1.0 x 106 CFU and were
administered in 100 L volumes.  Mice were observed three times per day for clinical signs
of infection as described in Table 2. Body temperature was monitored once daily using a
Fluke-566 infrared thermometer (Fluke Corporation, Everett, WA).  Mice that became
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moribund (Table 2) were euthanized by CO2 asphyxiation and necropsied. After euthanasia,
blood was collected via cardiac puncture, and the right lung and spleen were collected to
measure bacterial burden.
Results and Discussion
Bacterial Challenge in C57BL/6 Mice
The S. pneumoniae strain A66.1 showed an expected increased rate of mortality with
higher bacterial CFU inoculations in the C57BL/6 mice, but a challenge dose of 3.5 x 106
CFU was required to induce greater than 50 % mortality (Figure 10, part A).  Based on these
results, as well as the variability observed following intravenous inoculation of C57BL/6
mice with S. pneumoniae strain TIGR4 (data not shown), lethal CFU dose titration
inoculations were also performed by challenging mice via the intraperitoneal route.
Challenging the C57BL/6 mice via the intraperitoneal route proved to induce 100 %
lethality in all CFU doses within 48 hours of infection (Figure 10, part B).  This data
indicates that C57BL/6 mice are much more sensitive to an intraperitoneal challenge that
they are to an intravenous challenge. Studies have shown that injection with fungal zymosan
polysaccharide mixtures induce increased fluid permeability across peritoneal membranes
and soluble bacterial components such as lipopolysaccharide from Gram-negative bacteria
can reach the blood stream and promote amplified cytokine production (57) and greater
systemic immune responses in C57BL/6 mice (47, 57).  It can then be hypothesized that
capsule producing bacteria, from the combination of its secreted polysaccharide capsule and
various protein components, may induce a more vigorous and potentially tissue damaging
inflammatory response in the mouse.  This route of infection also poses a problem of reliably
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Table 2.  Clinical signs of infection scoring system for Streptococcus pneumoniae infection in mice. Post-
inoculation mice were monitored three times per day for outward signs of infection.  Mice were handled in a
biosafety cabinet for daily temperature readings and responsiveness assessment when higher infection scores
were given.  Mice were removed from the study and euthanized by CO2 asphyxiation and necropsied upon
receiving a score of 5.  Mice with fever readings received a “+” in addition to their recorded score for the
specified time.  Protocol was approved by the Iowa State University Institutional Animal Care and Use
Committee
Clinical Signs of Infection Scoring System
Score Physical Signs Assessment Method
1 Normal appearance and movement Visual
2 Ruffled fur Visual
3 Hunched back Visual
4 Lethargic movement but responsive Visual
Response to new stimuli, e.g.:
 food on cage floor
 reorientation in cage
5 Moribund, unresponsive, unable to
right itself
Visual
Response to new stimuli, e.g.:
 food on cage floor
 reorientation in cage
Body temperature < 25oC
+ Fever Infrared thermometer reading on back
 + 2oC above pre-infection reading
producing such a low CFU dosage repeatedly over time, increasing the likelihood of
unintentionally inducing overt and lethal inflammatory responses in the mice in future
experiments.
Bacterial Challenge in CBA/N Mice
Due to the inconsistencies observed using C57BL/6 mice in intravenous and
intraperitoneal bacterial challenges, the use of CBA/N mice was pursued for the remaining
experiments.  The CBA/N mice were inoculated intravenously by the tail vein and observed
for 7 - 14 days post-infection (DPI).  In this mouse strain, a predictable increase in mortality
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was seen with increasing the CFU of the challenge dose (Figure 11), and the 1 x 106 CFU
dose was 100 % lethal within 5 DPI. The time it took for mice to succumb verified that the
1 x 106 CFU was not overwhelming (which results in a quick death) but was enough of a
bacterial challenge to use for the infection model.
A
B
Figure 10. Streptococcus pneumoniae strain A66.1 dose titration challenge in C57BL/6 mice. Mice were
inoculated with increasing doses of S. pneumoniae A66.1 by A) intravenous administration of 200 µL
containing  between 200 and 3.5 x 106 CFU into the tail vein, or B) intraperitoneal administration 100 L
containing between 200 and 1.0 x 106 CFU.  Bacteria were cultivated overnight in BHI broth supplemented
with 5% yeast extract to an OD600 of 0.45-0.50 and diluted in PBS. The mice were monitored daily for clinical
signs of infection as described in the Appendix Materials and Methods. Mouse numbers n = 8 per group for
the intravenous challenge (A) and n = 6 per group for the intraperitoneal challenge  (B).
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Figure 11.  Intravenous challenge of CBA/N mice with S. pneumoniae strain A66.1 dose titration. Mice
were inoculated with S. pneumoniae doses ranging from 200 CFU to 1.0 x 106 CFU. Bacteria used for the
challenge experiments was cultivated as described in the Appendix Materials and Methods section. Briefly, S.
pneumoniae A66.1 was incubated overnight in BHI broth supplemented with 5% yeast extract to an OD600 of
approximately 0.45-0.50 and diluted in PBS.  The mice were infected intravenously in a 200 L volume into the
tail vein. The mice were monitored daily for signs of infection and clinical disease. Mouse numbers n = 4 to 9
per group.
Conclusions
The results obtained following the intravenous infection of C57BL/6 mice with S.
pneumoniae strain A66.1 were inconsistent with previously published reports (16, 17, 36, 84)
in that the survival rate was high for mice challenged with large numbers of S. pneumoniae
(e.g., > 1.0 x 106 CFU).  Because of these inconsistencies, it was determined that a model
employing an intravenous challenge of S. pneumoniae A66.1 in C57BL/6 mice would not be
optimal to evaluate the efficacy of an anti-pneumococcal vaccine.  In contrast, infecting
C57BL/6 mice via the intraperitoneal route proved overly sensitive as evidenced by the fact
that as little as 222 CFU of S. pneumoniae A66.1 proved overwhelmingly fatal within 48
hours of inoculation.  Finally, these studies demonstrated that CBA/N mice provided a more
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reproducible S. pneumoniae systemic challenge model and, therefore, these mice were
chosen for the vaccine studies described previously.
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